[ET Net News Agency, 30 July 2021] Sino Biopharmaceutical Limited (01177) said
"Edaravone Injection" (Brand name: Fenghaiyi) (Approved specification: 20ml: 30mg), a
brain neuroprotective agent developed by the group, has obtained drug registration
certificate granted by the National Medical Products Administration of the People's
Republic of China. The product was filed as a Chemicals Category 3 drug, and is deemed to
have passed the Consistency of Quality and Efficacy Evaluation for Generic Drugs.
Edaravone is a free radical scavenger, which can reduce brain oedema and tissue damage,
and effectively protect brain nerves. It can be used not only in the treatment of acute
cerebral infarction and cerebral embolism with bleeding tendency, but also in the
treatment of the rare disease amyotrophic lateral sclerosis. (RC)